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(presented  by  the  Commission  pursuant  to Article  149(3) 
~'-----~- of  the  EEC-Treaty) - 1  -
EXPLANATORY  MEMQRANDUM 
BACKGROUND 
In  November  1988  the  Commission  presented  to  the Council  a  proposal  for  a  Counci 1 
Directive on  the  legal  protection of  biotechnological  lnventions.1 
The  Economic  and  Social  Committee  delivered  Its opinion on  26  April  1989.2 
Parliament  discussed  the  proposal  at  length  in  committee  and  In  plenary  In  April 
and  October  1992.3 
The  amended  proposal  Is  l.ntended  to  take  account  of  these opinions. 
Parliament  concentrated mainly  on  the  ethical  dimension  of  biotechnological 
Inventions.  As  the  discussions  progressed,  It  became  clear  that  a  mere  reference 
to  the  concepts of  public pol icy  ("ordre  public")  and  morality was  not  enough  and 
that  this traditional  framework  for  exclusion  from  patentability needed  to  be 
supplemer.ted  by  more  precise guidelines  for  national  patent offices and  courts. 
Such  Is  the object of Article 2 of  the  amended  proposal. 
Parliament  adopt~u by  a  very  large majority an  amendment  concerning what  is 
commonly  known  as  farmer's  privilege.  The  Commission,  though  Initially opposed 
to  the amendment,  has  finally  accepted  It  to  allow  the  Council  to discuss  It  as 
part of  a  continuing cooperation  procedure.  This amendment  by  Pari lament  Is  to 
be  found  In  Article 13  of  the  amended  proposal. 
1  OJ  No  C 1  0,  13 . 1 . 1989 ,  p .  3 . 
2  OJ  No  C 159,  26.6.1989,  p.  10. 
3  OJ  No  C - 2  -
The  Question of  the  compatibility  between  the  proposal  for  a  Directive  and  the 
Nairobi  Convention on  Biological  Diversity,  which  was  signed at  the  Earth  Summit 
In  Rio  de  Janeiro on  5  June  1992,  was  also discussed  in  depth  by  Parliament.  The 
conclusion  reached was  that  the  proposal  for  a  Directive was  perfectly compatible 
with  the Convention's objectives. - 3  -
CQMUENTARY  ON  THE  RECITALS 
Fourth  and fifth recitals 
These  two  new  recitals replace  the  fourth  recital  of  the original  proposal. 
Their  purpose  Is  to make  clear  that the  rules of  national  patent  law  remain  the 
essential  basis  for  the  legal  protection of  biotechnological  inventions.  The 
proposal  for  a  Directive  therefore  In  no  way  seeks  to create a  separate body  of 
law,  but  Is  Intended only  to clarify  the  existing  law  in  order  that  it  might  be 
applied correctly  to  such  Inventions. 
Seventh  to thirteenth recitals 
These  new  recitals,  which  were  not  in  the original  proposal,  deal  with  the 
•ethical  question"  raised  by  the Commission's  proposal.  Although  this ethical 
question was  not  mentioned explicitly at  the outset,  this does  not  mean  that  the 
Commission  did  not  consider  It  Important  or  that  It  denied  It  existed.  In  the 
first  place,  the  traditional  exceptions  to patentabll lty,  Including  that  relating 
to public policy and  morality,  are enshrined  In  national  law  and  can  therefore 
still  appiy.  And  In  the  second  place,  the ethical  question  Is essentially, 
covered  by  rule~ for  safeguarding  human  rights  in  relation  to  the  appl icatlons of 
research  and  the monitoring of  Its results or  their  commercialization.  Such 
rules fall  outside  the  scope of  patent  law.  The  best  known  example  Is. that of. 
the  body  of rules concerning authorizations  to market  medicinal  products,.whlch 
exist  separately  from,  and  must  be  compl  led  with  Independently of,  the  patent  law 
provisions applicable  to that  area of  technology.  It  can,  of  course,  be  argued 
that,  In  so  far  as  the  technology  to  be  protected might  affect  the  genetic 
make-up  of  living matter,  Including  that  of  human  beings,  controls must  be 
Introduced or  prohibitions  laid  down.  The  Commission  agrees with  this point  of 
view. - 4  -
The  Commission  recognizes,  however,  that,  although  the  purpose of  the  proposal 
for  a  Directive  is merely  to  harmonize  laws  on  patents protecting 
biotechnological  Inventions  and  not  to establIsh  a  set of  European  ethical 
principles,  It  Is essential,  in  the  I lght of  all  that  has  been  said since  the 
original  proposal  was  publ lshed,  not  least within  Parliament,  that  patent  law 
should  contain certain  Impassable  barriers so as  to provide guidance  for  those 
Interpreting  the  concepts of  public  pol icy  and  morality. 
ConseQuently,  the  COmmission  considers  that  three  types of  Invention must  be 
excluded  from  patentability:  the  human  body  or  parts of  the  human  body  oer  se, 
certain processes  for  modifying  the  genetic  Identity of  human  beings,  and  certain 
processes  for  modifying  the genetic  identity of  animals. 
Questions  relating to  the monitoring of  the applications of  research  and  of  the 
use or  commercialization of  its results are  reserved  for  other  national  or 
Community  laws.  Patent  law  should  go  no  further  than  it  does  as  rules on  these 
matters are out  of  place  In  It:  Member  States may  enact  such  rules  as  they  see 
fit,  subject  to any  Community  measures  that  may  be  in  force.  For  example, 
Council  Decision 90/395/EEC  of  29  June  1990  adopts  a  specific  research  and 
technological  development  programme  In  the  field of  health:  human  genome 
analysis  (1990  to 1991)  and  provides  for  a  study of  the ethical,  social  and  legal 
aspects. 
A number  of  specific programmes  Implementing  the  third  framework  programme  for 
research  and  technological  development  (1990  to  1994)  include evaluations of  the 
economic  and  social  Impact  and  of  any  technological  risks.  For  example,  Council 
Decision  91/505/EEC  of  9  September  1991  adopting  the  specific programme  In  the 
field of  biomedicine  and  health  pays particular  attention  to  the ethical,  social - 5  -
and  legal  aspects,  and  Includes  research on  biomedical  ethics;  and  Councl I 
Decision 92/218/EEC of  26  March  1992  adopting  the specific programme  In  the  field 
of  biotechnology  takes  Into account  the ethical,  social  and  ecological 
Implications of  research.  On  20  November  1991  the  Commission  set  up  an  advisory 
body  for  all  questions  to do  with  the ethical  Implications of  biotechnology. 
TwentY-fifth  and  twenty-seventh  recitals 
These  new  recitals reflect  the  new  wording  of  the  corresponding articles. 
The  Commission  has  not  accepted Parliament's amendments  Nos  1  to 8  introducing 
new  recitals as  It  considers  that  they  are unrelated  to  the  proposal's objective 
and  do  not  shed  any  light  on  its substantive  terms. - 6  -
COMMENTARY  ON  THE  ARTICLES 
Article 1 
The  new  wording  seeks  to bring out  more  clearly the  fact  that  the ordinary  rules 
of  patent  law  apply,  subject  to  the  provisions of  the  Directive. 
The  proposed  wording  reproduces  the  terms of  Parliament's amendment  No  9. 
The  Commission  has  not  accepted  Parliament's amendments  Nos  10,  11  and  12.  It 
considers amendment  No  10  unnecessary  In  the  I lght  of existing  law,  notably 
Article 69  of  the· Munich  Convention  on  the Grant  of  European  Patents.  As  for 
amendments  Nos  11  and  12,  these  are out  of  place  in  a  directive  harmonizing 
national  laws  as  the  latter  already  have  to  take  account  of  the  conventions 
referred  to therein. 
Article 2 
In  paragraph  1  the concept  of  biological  material  replaces  that of  living matter. 
The  proposed wording  reproduces  the  terms of  Parliament's  amendment  No  13. 
Paragraph  2  defines  the  concept  of  biological  material  and  replaces Article  19  of 
the original  proposal. 
The  proposed  wording  Is  based on  Parliament's  amendment  No  14. 
Paragraphs  3  and  4  are  the  concrete  formulation  of  the explanations given  In 
connection with  the  sixth  to  thirteenth recitals. - 7  -
The  first  subparagraph of  paragraph  3  Is  based on  Parliament's  amendment  No  16. 
The  examples  given  In  the  second  subparagraph of  paragraph  3  are  intended  as  an 
aid  to  Interpreting  the  concept  of  public pol icy or  morality. 
With  regard  to  the unpatentabi lity of  the  human  body  or  parts of  the  human  body, 
the Commission  wishes  to make  It  quite clear,  In  keeping  with  the  discussions 
that  have  taken  place within  Parliament,  that  "parts of  the  human  body"  per  se 
means  parts of  the  human  body  as  found  Inside  the  human  body.  It  Is  Important 
that  this be  spelled out  so as  to  remove  all  possible  ambiguity  with  respect  to 
the position of certain products or  parts of  the  human  body  which  are  already 
covered  by  patents granted  In  connection with  the  development  of medicinal 
products:  e.g.  a  human  lymphoblastoid cell  line  (European  patent  No  0113.769  81 
granted on  15  February  1989);  a  recombinant  DNA  molecule  capable of  Inducing  the 
expression  In  a  unicellular  host  of  a  polypeptide displaying  the  Immunological  or 
biological  activity of  human  a-Interferon  (European  patent  No  0041.313  81  granted 
on  12  September  1990);  a  human  hepatocyte  culture process  (European  patent 
No  0143.809 81  granted on  18  January  1989);  the molecular  cloning  and 
characterization of  a  gene  sequence coding  for  human  relaxin  (European  patent 
No  0101.309 81  granted on  16  September  1991);  a  method  for  producing  human 
antibody  (European  patent  No  0096.839  81  granted on  25  January  1989);  and  a 
process  for  producing a  human  protein of  therapeutic value  (French  patent 
No  2.637613  81  granted on  27  September  1991). 
It  goes without  saying  that,  If  the  applicant  simply wishes  to patent  a  mere  part 
of  the  "human  body"  per  se,  e.g.  a  human  gene  neither the function of  which  nor 
the  protein  for  which  It  codes  is known,  exclusion  from  patentability would 
apply. 
The  proposed  wording  Is  based on  Parliament's  amendment  No  15 .. - 8  -
The  second exclusion  In  principle  from  patentabl 1 tty concerns  processes  for 
modifying  the genetic  Identity of  human  beings  for  a  non-therapeutic  purpose 
which  Is  contrary  to  the  dignity of  man  (point  (b)  of  the  second  subparagraph  of 
paragraph  3).  Nowadays  the  tools of  genetic engineering  can  be  used  to diagnose 
genetic diseases at  gene  level,  whether  directly or  indirectly and  at  any  stage 
in  the development  of  a  human  being,  starting  from  conception.  ConseQuently,  it 
Is  possible  to envisage  the application of  genetic engineering  techniQues  to 
manipulations of  the  human  genome  with a  view  to obtaining a  lasting modification 
thereof.  In  the  case of  human  beings,  these manipulations would  be  designed 
above  all  to correct  selectively a  genetic defect  by  introducing a  normal  gene, 
if  possible  in  place of  the corresponding  defective gene.  However,  such 
"germinal"  gene  therapy  is still more  or  less at  the stage of  experimentation on 
animals  and  human  cell  cultures.  In  practice,  such  manipulations  can  be  carried 
out  only  in  the  context of  in  vitro fertilization,  and  genetic correction at  the 
stage  preceding  implantation of  the embryo  is sti I I  some  way  off as  the  proper 
functioning  of  a  foreign  gene  has  yet  to be  mastered. 
The  other  type of  gene  therapy  Is  known  as  "somatic"  gene  therapy.  It  consists 
In  trying  to cure  the somatic cells of  an  existing  human  being without  modifying 
his germ  cells.  Hence  the genetic change  brought  about  In  the  patient  is  not 
hereditary,  in  contrast  to what  might  happen  in  the  case of  germinal  gene 
therapy.  The  proposed exclusion  from  patentability does  not  cover  the  processes 
used  In  somatic  gene  therapy. 
Through  the  proposed wording,  the  Commission  Is seeking  to  leave open  the 
possibi I ity of  granting  legal  protection to  inventions  capable of  improving 
considerably  the  lot  of certain human  beings suffering  from  deep-seated  illness. 
The  fact  that  It will  still  be  some  time  before  this  type of  Invention  actually 
sees  the  light  of  day  Is  no  bar  to  Its being  already contemplated  In  the  proposal 
for  a  Directive.  On  the contrary,  the  prospect  of  protection cannot  but - 9  -
encourage  investment  In  this field.  As  regards  the  spectre of  eugenics which  Is 
sometimes  raised  by  those  who  warn  against  this  type of  research  and  the 
uncontrolled applications  it would  permit.  It  Is  Important  to note  the  coupling 
of  the  condition of  the  therapeutic purpose of  those  processes  for  modifying  the 
genetic  Identity of  human  beings which·  are capable of  being  patented with  that  of 
conformity with  the  dignity of  man. 
In  the course of  the discussions within Parliament,  it became  apparent  that  a 
distinction had  to be  drawn  between.  on  the one  hand,  methods  for  treatment  by 
surgery or  therapy  and  diagnostic methods.  which  are not  considered  Inventions 
susceptible of  Industrial  application and  which  are  therefore unpatentable.  and, 
on  the other.  biotechnological  processes  Involving modification of  the genetic 
Identity of  human  beings which  have  a  therapeutic  purpose  In  Keeping  with  the 
dignity of man.  Use  of  the expression "therapeutic purposeM  to describe an 
Invention which  may  be  patentable  from  an  ethical  point  of  view  could create  the 
Impression  that  that  which  is declared  technically unpatentable,  notably  in 
Article 52(4)  of  the Munich  Convention  on  the  Grant  of  European  Patents.  would 
become  patentable  In  the case of  biotechnological  inventions.  In  order  to avoid 
this ambiguity  due  to an  overlapping of  the similarly worded  technical  standard 
and  ethical  standard,  It  seems  appropriate  to stress the unpatentablllty of 
certain methods,  whatever  their  technical  characteristics,  In  the sphere of 
biotechnology.  The  amended  proposal  accordingly  reproduces  the wording  of 
Article 52(4)  of  the Munich  Convention  in  Article 8  and  not  In  Article  2,  which 
has  been  specifically extended compared  with  the original  proposal  to  Include  the 
ethical  dimension  capable of  being dealt with  by  patent  law.  Thus  the  ethical 
control  introduced by  point  (b)  of  the  second  subparagraph of Article  2(3)  of  the 
amended  proposal  may  exclude certain  Inventions  from  patentability even  If  they 
are patentable under  Article 8. 
The  proposed  wording  Is  based on  the  second  and  fourth  paragraphs of  Parliament's 
amendment  No  20. - 10  -
The  third exclusion  In  principle from  patentabl llty concerns  processes  for 
modifying  the genetic  Identity of  animals which  are  likely  to  Inflict suffering 
or  physical  handicaps upon  them  without  any  benefit  to man  or  animal  (point  (c) 
of  the second  subparagraph of  paragraph  3).  The  techniQues  for  producing 
transgenic animals  are well  known  and  have  been  described  In  detail,  and  seek, 
among  other  things,  to create  laboratory  animals  (e.g.  Harvard  University's 
"onco-mouse")  or  animals which  produce,  via  a  tumour  cell  developing  as  a  result 
of  gene  therapy,  effective secretions of  foreign  proteins of  therapeutic value, 
for  example  neutrophil  elastase  Inhibitor  Intended  for  the  treatment of  pulmonary 
emphysema,  thrombotic  disorders  and  hypertension  (as  Is  the case with  the 
transgenic mouse  of  the  French  company  Transgene,  patent  No  2.637613 81  referred 
to above). 
In  view of  the usefulness of  this  type of  Invention  to man's  well-being,  In  this 
Instance  his  health,  the Commission  considers  It only  right  and  proper  that 
Investment  in  research  thereon should  be  capable of  being  duly  protected.  The 
Commission  also considers  that  the borderline between  what  is acceptable  and  what 
Is  not  acceptable must  take  account of  the criterion of  animal  suffering.  The 
Commission  acknowledges  that  this criterion may  be  difficult  to evaluate.  but  It 
believes that  Its  Inclusion  Is  necessary  In  order  to avoid  the gratuitousness of 
certain experiments which  may  be  Inflicted on  animals  In  so  far  as  they  are out 
of all  proportion  to the objectives pursued.  While  It  Is  concerned  about  certain 
extreme situations  In  which  animals may  find  themselves  In  some  laboratories,  the 
Commission  must  neverthless point out  that  patent  law  Is  not  the appropriate 
field  In  which  to  legislate thereon.  The  preamble  to the  European  Convention  for 
the Protection of Vertebrate Animals  used  for  Experimental  and  Other  Scientific 
Purposes  signed at  Strasbourg on  18  March  1986  sets out  clearly the  framework 
within which  vertebrate animals  may  be  used  with  reference  to  their  usefulness  to 
man  and  to  the suffering  they  may  endure  as  a  result: - 11  -
"Recognising  that  man  has  a  moral  obligation to  respect  all  animals  and  to have 
due  consideration for  their  capacity  for  suffering and  memory; 
Accepting  nevertheless  that  man  In  his Quest  for  knowledge,  health and  safety has 
a  need  to use  animals where  there  Is  a  reasonable expectation  that  the  result 
will  be  to extend  knowledge  or  be  to  the overall  benefit of  man  or  animal,  just 
as  he  uses  them  for  food,  clothing and  as beasts of  burden; 
Resolved  to  limit  the use of  animals  for  experimental  and  other scientific 
purposes,  with  the  aim  of  replacing such  use  wherever  practical,  In  particular  by 
seeking alternative measures  and  encouraging  the use of  these alternative 
measures; 
Desirous  to adopt  common  provisions  In  order  to protect  animals  used  In  those 
procedures which  may  possibly cause  pain.  suffering,  distress or  lasting harm  and 
to ensure  that  where  unavoidable  they shall  be  kept  to a  minimum." 
Besides Belgium,  Denmark.  France,  Germany,  Greece.  the  Netherlands,  Spain and  the 
United  Kingdom,  the  European  Communities  as such  signed  the Convention,  and  on 
24  November  1986  the Council  adopted  Directive 86/609/EEC  on  the approximation of 
laws,  regulations and  administrative provisions of  the Uember  States  regarding 
the  protection of  animals  used  for  experimental  and  other scientific purposes.1 
In  1992.  moreover,  the  Commission  set  up  at  the  JRC's  lspra establishment  a 
laboratory  responsible  for  validating,  at  Community  level,  alternative methods 
for  reducing  the  number  of  animals  used  for  experimental  purposes  and  their 
degree of suffering. 
The  wording  proposed  for  point  (c)  of  the second  subparagraph of Article  2(3) 
thus  reproduces  the  two  basic  Ideas  underlying  amendments  Nos  17  and  18  and 
amendment  No  19  and  already  sanctioned  by  the  Council  Directive of 
24  November  1986:  an  Invention which  has  the effect of  inflicting suffering on 
an  animal  Is excluded  from  patentability,  unless  It  may  be  beneficial. 
1  OJ  No  L 358 ,  18 . 1  2 . 1986,  p .  1 . - 12  -
As  far  as  the  scope of  paragraph  4  Is  concerned,  the  following  Instruments can  be 
mentioned  by  way  of  example:  Directives 90/219/EEC  and  90/220/EEC  of 
23  April  1990  on  the contained use of genetically modified  micro-organisms  and  on 
the deliberate release  Into  the environment  of  genetically modified organisms; 
French  Decree  No  83  132  setting up  a  National  Advisory  Committee  on  Ethics  In 
Life  and  Health  Sciences.;  the German  Act  of  30  October  1990  on  the protection of 
embryos;  the  Danish  Act  of  3  June  1987  on  an  Ethics Council  and  the  regulation of 
certain forms  of  biomedical  experimentation;  the  United Kingdom  Human 
Fertilization and  Embryology  Act  1990;  the  Spanish Act  of  28  December  1988  on  the 
donation  and  utilization of  human  embryos  and  foetuses  and  their cells,  tissues 
and  organs;  the Portuguese Act  of  9  June  1990  setting up  a  National  Council  on 
Ethics  In  Life Sciences;  the  Italian Decree  of  28  March  1990  setting up  a 
National  Committee  for  Bloethlcs;  the German  Act  of  20  June  1990  on  gene 
technology;  and  the Belgian Act  of  14  August  1986  on  the  protection and  welfare 
of  animals. 
It  should be  noted,  moreover,  that  a  framework  convention on  bloethics  Is  being 
prepared by  the Council  of  Europe.  Mention  should also be  made  of  Parliament's 
Resolution of  16  March  1989  on  the ethical  and  legal  problems  of  genetic 
engineering. 
The  Commission  has  not  accepted  Parliament's amendment  No  21  as  It  goes  beyond 
what  patent  law  can  monitor  by  way  of  the examination of  patent  applications 
filed with national  offices.  As  already  Indicated  In  the comments  on  the  seventh 
to  thirteenth recitals,  a  global  ethic of  research  and  of  the  Information  It 
generates must  not  be  drawn  up  within  the specialized framework  of  patent  law. 
If  necessary,  a  suitable set of  rules meeting  the  concerns which  motivated 
amendment  No  21  could  bring  its  Influence  to bear  In  the  light  of  Article  2(4)  of 
the  amended  proposal. 
The  Commission  has  not  accepted  the  second  part of Parliament's amendment  No  47 
as  It  contains a  traditional  principle already enshrined  In  the Munich  Convention 
on  the Grant  of  European  Patents  (Article 52(2)(a))  and  Incorporated  In  the  taws 
of  the Member  States. - 13  -
Article 3 
T.he  new  wording  proposed  for  Article 3 simplifies and  corrects  the original 
proposal  as  regards  the patentability of  biological  material. 
The  proposed  wording  Is  based on  Parliament's amendment  No  22. 
Article 4 
The  wording  proposed  for  Article 4  is  intended  to be  more  precise. 
The  COmmission  has  not  accepted Parliament's amendment  No  23  relating to 
Article 4.  This article does  not  deal  as  such  with  processes  for  the  production 
of  the biological  material  forming  the  subject-matter of Articles 5  and  6  of  the 
amended  proposal.  It  simply states  that  use of  plant or  animal  varieties or of 
the  processes  for  their  production does  not  imply  the unpatentablllty of  the 
Invention  In  which  It  occurs. 
\ 
Article 5 
The  wording  proposed  for  Article 5  groups  together  Articles 5  and  6 of  the 
original  proposal  dealing with microbiological  processes consisting of one  or 
more  steps. 
The  wording  proposed  for  paragraph  2  reproduces  the  terms  of Parliament's 
amendment  No  24. - 14  -
Article 6 
The  wording  proposed  for  Article 6  Is drawn  from  the  terms of  Article 7  of  the 
original  proposal  concerned with essentially biological  processes which  are not 
patentable. 
The  proposed  wording  Is  based on  Parliament's amendment  No  25. 
Article 7 
The  wording  proposed  for  Article 7  corresponds  to that  of Articles 8  and  9  of  the 
original  proposal  regarding biological  material  forming  part of  an  existing 
material  and  capable of  being patented. 
Article 8 
As  already  Indicated  In  connection with  point  (b)  of  the second  subparagraph of 
Article 2(3)  of  the amended  proposal,  this article reproduces,  In  the  Interests 
of clarity,  the  terms of Article 52(4)  of  the Munich  Convention on  the Grant  of 
European  Patents.  The  article replaces Article 18  of  the original  proposal. 
The  proposed  wording  Is based on  the  first  and  third paragraphs of  Parliament's 
amendment  No  20. 
Article 9 
The  wording  proposed  for  Article 9  taKes  up  again  the  Question of surgical  or 
diagnostic methods  covered by  Article 8  In  so  far  as  they  constitute a  step  In  a 
process patentable as  a  whole. - 15  -
Article 10 
The  wording  proposed  for  Article 10  deals,  using  a  different  phraseology  from 
Article 12  of  the original  proposal,  with  the  question of  the extent of  the 
protection conferred  by  a  patent on  a  biological  material  having  specific 
characteristics or  of  the  protection conferred  by  a  patent on  a  process  for  the 
production of  a  biological  material  having specific characteristics. 
The  proposed  wording  Is  based  on  Parliament's amendments  Nos  29  and  31. 
Article 11 
The  wording  proposed  for  Article  11  deals,  using  a  different  phraseology,  with 
the principle of  a  specific exhaustion  In  certain circumstances of  a  patentee's 
rights  in  a  biological  material.  This question was  dealt with  In  Article  11  of 
the original  proposal. 
The  proposed  wording  reproduces  the  terms of  Parliament's amendment  No  30. 
Article 12 
The  wording  proposed  for  Article 12  reproduces  in  a  corrected  form  that  proposed 
for  Article 13  of  the original  proposal  concerning  the extent of  the protection 
conferred on  a  product  containing or  consisting of  genetic  information, 
Irrespective of  its parentage,  which  is dealt  with  in  Article 10.  The  Commission 
has  therefore  not  accepted  Parliament's amendment  No  33  aimed  at  deleting 
Article 13  of  the original  proposal. - 16  -
Article 13 
During  the discussions within Parliament,  the  question of  "farmer's ~rivllege", 
that  Is  to say  the possibility for  a  farmer  to use  part of  his  harvest  to resow 
his fields,  became  the key  Issue,  so much  so that  Pari lament  twice  referred  the 
proposal  for  a  Directive back  to  its  legal  affairs Committee  because  the 
Commission,  for  legal,  technical  and  economic  reasons,  did  not  accept  farmer's 
prIvilege. 
However,  the  fact  that  the vast  majority of  Parliament's members  are  In  favour  of 
Introducing  farmer's  privl lege  into patent  law  is  a  political  sign which  the 
Commission  cannot  Ignore  in  the  context of  a  cooperation procedure.  This  Is all 
the more  true as  the  lack  of  a  solution to  the  problem  would  prevent  work  from 
continuing on  the  proposal  for  a  Directive as  a  whole  despite  Its having  been 
before  the Council  and  Parliament  since  the beginning of  1989.  By  accepting 
farmer's  privilege,  the Commission  is seeking first  and  foremost  to unblock  the 
cooperation  procedure  so as  to enable  the  Council  to state  Its position on  the 
proposal  as  amended  in  the  light  of  Parliament's  amendment  and  to examine 
Parliament's  reasons. 
The  first  argument  put  forward  by  Parliament  concerns  the  current  farming 
practice of  using part of  the  harvest  as  seeding material.  This ·practice could 
be  called  Into question  In  the case of  seeds patented  following  genetic 
manipulations  because  the  patent  holder  would  enforce his rights against  certain 
usages established and  recognized  as  part of  the  legal  protection ~!ready 
available  to  the  farming  community,  namely  breeders'  rights. 
The  second  argument  put  forward  by  Parliament  relates to  the ability of  the 
patent  holder  to monitor  closely what  ml.ght  be  happening  on  a  farm. ,) 
- 17-
The  third argument  put  forward  by  Parliament  is an  economic  one.  If  there were 
no  farmer's  privilege,  the  scope  of  patent  law  would  be  such  that  farmers  might 
have  to  pay  a  royalty on  each  generation of  seed. 
Since  the  vast  majority within  Pari lament  are  in  favour  of  farmer's  privilege, 
and  since. this  view  was  expressed with  vigour,  the Commission  has  accepted 
Pari lament's amendment  No  32  so as  to unblocK  the cooperation  procedure,  as 
Indicated  above. 
It  Is  Important  to note  that,  In  Parliament's amendment  and  In  the  text  of  the 
amended  proposal,  the concept  of  farmer's  privl lege  does  not  appear  as  such,  but 
takes  the  form  of  a  derogation  from  the extent  of  the  protection conferred  by  a 
patent.  Like  Pari lament,  the  Commission  acknowledges,  moreover,  that  the 
subject-matter of  the  harvests  and  the  I lvestock of  a  farmer  must  be  dealt  with 
in  the  same  way. 
The  COmmission  Is  fullY  aware,  however,  that  farmer's  privilege must  not  make 
possible under  patent  law  that  which  is  forbidden  under  plant  variety protection 
law,  resulting  In  certain areas of  agriculture or  horticulture,  such  as 
ornamental  plants,  fruit  trees or  vines,  being affected.  It  has  therefore 
reJected  the oral  amendment  added  by  Parliament's  legal  affairs Committee  with  a 
view  to  !nsc:;;ting  the words  "or  other  propagatable material" after  the  first 
occurrence of  the word  seed.  Thus,  as  far  as  the Commission  Is  concerned,  •seed" 
Is  to be  understood  In  the  narrow  sense. 
Article 14 
The  new  wording  proposed  for  Article  14  concerning  compulsory  licences envisages 
only  the posslbl lity of  granting such  I icences  where  It  is  in  the  public 
Interest. 
The  proposed  wording  is  based on  Parliament's amendment  No  34. - 18  -
Article 15 
The  new  wording  proposed  for  Article  15  concerning  the  deposit,  under  certain 
conditions,  of  the  biological  material  forming  the subject-matter of  an  Invention 
has  been greatly slmpl lfied compared  with Article  15  of  the original  proposal. 
In  this highly  technical  field,  which  is of  concern mainly  to patent offices  In 
their  dally work  when  they  are called upon  to consider  whether  the  reQuirement  as 
to sufficient disclosure of  an  Invention  is satisfied,  it  is much  better  to apply 
existing.  time-tested principles.  Hence  the  reference  to  the Budapest  Treaty on 
the  International  Recognition of  the  Deposit  of  Microorganisms  for  the  Purposes 
of  Patent  Procedure of  2B  Apri I  1977,  such  reference  being  both  necessary  and 
sufficient. 
The  proposed  wording  Is  based on  Parliament's amendments  Nos  35  to 40. 
Article 16 
The  new  wording of Article  16  Is  a  highly simplified version of Article 16  of  the 
original  proposal.  the  reference  to  the Budapest  Treaty of  28  Apr I I  1977  being 
sufficient  to deal  with  the  QUestion  of  new  deposits of  biological  material  In  so 
far  as  alI  Member  States will  have  to  become  parties to  that  Treaty  by  virtue of 
the  proposal  for  a  Directive. 
The  proposed  wording  reproduces  the  terms of  Parliament's  amendment  No  41. 
Article 17 
The  new  wording  of Article  17  concerning  reversal  of  the  burden of  proof  has  been 
brought  fully  Into  line with Article  35  of  the  Luxembourg  Convention  for  the 
Community  Patent. 
The  proposed  wording  Is  based on  Parliament's amendment  No  42. - 19  -
Article 18 
The  proposed  wording  reflects Pari lament's  amendment  No  45. 
The  content  of  Article  10  of  the original  proposal  -use for  experimental 
purposes- has  not  been  Included  as  It  has  become  apparent,  following  discussion 
of  Pari lament's  amendment  No  26,  which  the Commission  has  rejected,  that  It  Is 
Inappropriate  In  view of  the ordinary  rules of  patent  law.  Parliament's 
amendments  Nos  27  and  28,  which  also concern Article 10  of  the original  proposal, 
have  I lkewlse  been  rejected by  the COmmission,  the  former  because  It  Is 
unnecessary  In  the  light of  present-day patent  law,  and  t~e  latter  because  It  Is 
incompatible with  the  current  position with  regard  to patents  for  pharmaceutical 
products  and  hence  would  give  rise  to discrimination. .  '· 
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'.f'  AMENDED  PROPOSAL  FOR  A COUNCIL  DIRECTIVE  ON  THE 
LEGAL  PROTECTION  OF  BIOTECHNOLOGICAL  INVENTIONS 
(presented by  the Commission  pursuant  to 
Article 149(3) of  the  EEC  Treaty) 
.  ·~  ' 
!.  .• OR I  Gl NAL  PROPOSAL 
·····' 
>  .. ~THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES,  ·  .. 
·,Having  regard  to  the  Treaty  establishing 
the  European  Economic  Community,  and  in 
<·,  ~·:particular  Article  100a  thereof; 
·.·Having  regard  to  the  proposal  from  the 
· ·  ..  Comm iss I  on , 
. .  ~In  .. cooper at ion  with  the  European 
~ar II ament, 
····Having  regard  to  the  opinion  of  the 
•  .. ~. 
..  :Economic  and  Social  Committee, 
.<..1>  Whereas  dIfferences  exIst  In  the  I  ega I 
p~otection  of  biotechnological  Inventions 
~offered  by  the  I  aws  and  practIces  of  the 
.....  Member  States  and  such  differences  could 
.:.·create  barriers  to  trade  and  to  the 
·creation  and  proper  functioning  of  the 
· ·.  interna I  market; 
. •; 
·,, 
·.·· 
AMENDED  PROPOSAL 
THE  COUNCIL  OF  THE  EUROPEAN 
COMMUNITIES, 
Unchanged 
Having  regard  to  the  proposal  from  the 
Commisslon,1 
In  cooperation  with  the  European 
Parllament,2 
Having  regard  to  the  opinion  of  the 
Economic  and  Social  Commlttee,3 
(1)  Unchanged 
1  OJ  No  c  1  0,  1  3. 1 . 1989,  p .  3 . 
2  OJ  No 
3  OJ  No  C 159,  26.6.1989,  p.  10 - 2  -
ORIGINAL  PROPOSAL 
(2)  Whereas  such  differences  In  legal 
protection  could  wei  I  become  greater  as 
Member  States  adopt  new  and  dIfferent 
legislation and  administrative practices or 
as  national  Jurisprudence  Interpreting such 
legislation 
differently; 
and  practices  develops 
AMENDED  PROPOSAL 
(2)  Unchanged 
.· ....  •  .. 
'·  ·-
·,•:.. 
•-,. 
,r ;:'::'· 
.. :'  ~ 
..  :  ... 
,,  . 
~  ''·  .· ·  . 
. .  _,  ~ 
_.,_ 
,._., 
'~ . 
·.  -·. 
:~.  :  .. - 3  -
ORIGINAL  PROPOSAL 
(3)  Whereas 
engineering 
and  genetic  biotechnology 
are  playing  an  increasingly 
broad  range·  of  important  role  in  a 
industries  and  the  protection  of 
biotechnological  Inventions  can  be 
considered  of  fundamental  Importance  for 
the  Community's  industrial  development; 
(4)  Whereas  the  patent  system must  adapt  to 
new  technological  developments  which  may 
involve  living matter  but  which  also fulfl I 
the  reQuirements  for  patentability; 
(5)  Whereas  no  prohibition  or  exclusion 
exists  in  national  or  international  patent 
Jaws  which  precludes  the  patentabi I ity  of 
living matter  as such; 
AMENDED  PROPOSAL 
(3)  Unchanged 
(4)  Whereas  the  legal  protection  of 
biotechnological  Inventions  does  not 
necessitate  the  creation  of  a  separate 
body  of  law  in  place  of  the  rules  of 
national  patent  law; 
(5)  Whereas  the  ru I  es  of  nat iona I 
patent  I  aw  remaIn  the  essent i a I  basis 
as  far  as  the  legal  protection  of 
biotechnological  inventions  is 
concerned;  whereas,  however,  they  must 
be  adapted  or  supplemented  in  certain 
specific  respects  in  order  to  take 
ful Jy  into  account  new  technological 
developments  which  may  involve 
biological  material  but  which  also 
fulfil  the  requirements  for 
patentab iII ty; 
(6)  Unchanged .. 
- 4  -
ORIGINAL  PROPOSAL  AMENDED  PROPOSAL 
(7)  Whereas  in  implementing  the 
Directive  regard  should  be  had  to 
ex 1st lng  national  patent  I  aws,  as 
amended  by  the  Directive;  whereas 
those  laws  contain  provisions  on  the 
criteria for  patentability or  exclusion 
from  patentabl I ity,  including 
provisions  to  the  effect  that  a  patent 
may  not  be  granted  in  respect  of 
inventions  the  publication  or 
exploitation of  which  would  be  contrary 
to  public  pol icy  ("ordre  pub I ic")  or 
morality; 
(8)  Whereas  it  is  desirable  to  include 
in  the  body  of  the  Directive  such  a 
reference  to  public  policy and  morality 
in  order  to  h lgh light  the  fact  that 
some  appl icatlons  of  biotechnological 
Inventions,  by  dint  of  their 
consequences or  effects,  are capable of 
offending against  them; 
(9)  Whereas  it  is  important  also  to set 
out  in  the  body  of  the Directive  a  list 
of  inventions  excluded  from 
patentability so  as  to provide  national 
courts  and  patent  offices  with  an 
essential  guide  to  interpreting  the 
reference  to pub I ic  pol icy  or  morality; - 5  -
ORIGINAL  PROPOSAL  AMENDED  PROPOSAL 
(10)  Whereas,  In  the  I lght  of  the 
general  principle  that  the ownership of 
human  beings  Is  prohibited,  the  human 
body  or  parts of  the  human  body  per  se 
must  be  excluded  from  patentabil lty; 
(11)  Whereas  processes  for  modifying 
the  genetic  Identity  of  human  beings 
for  a  non-therapeutic  purpose  which  is 
contrary  to  the  dignity  of  man  must 
also be  excluded  from  patentability; 
(12)  Whereas  processes  for  modifying 
the  genetic  identity  of  animals  which 
are  likely  to  inflict  suffering  or 
physical  handicaps  without  any  benefit 
to  man  or  animal  must  likewise  be 
excluded  from  patentability  In  so  far 
as  the  suffering  or  physical  handicaps 
inflicted  on  the  animals  concerned  are 
out  of  all  proportion  to  the  objective 
pursued;. 
(13)  hereas  this  Directive  is  without 
prejudice  to  national  and  Community 
laws  on  the  monitoring  of  the 
applications of  research  and  of  the use 
or  commercialization  of  its  results, 
notably  from  the  point  of  view  of  the 
requirements  of  public  health,  safety, 
the  protection of  the  environment,  the 
protection of  animals,  the  preservation 
of  genetic  diversity  and  compliance 
with  certain ethical  standards; (51 
- 6  -
ORIGINAL  PROPOSAL 
(6)  Whereas  national  patent systems  have  In 
the  past  successfully  adapted  to  technical 
developments  and  scientific  breakthroughs 
in  according  patent  protection  to  such 
developments  where  appropriate; 
(7)  Whereas  the  Investments  reQuired  In 
research  and  development  particularly  for 
genetic engineering are especially high  and 
especially  risky  and  the  posslbl llty  of 
recouping  that  Investment  can  only 
effectively  be  guaranteed  through  adeQuate 
legal  protection; 
(8)  Whereas 
approximated 
Uember  States 
wl thout 
protection 
of  the 
effective 
throughout 
Convnunl ty 
Investments might  well  never  be  made; 
and 
the 
such 
(9)  Whereas  some  Inventions 
through  biotechnology  and 
developed 
genetic 
engineering  are  at  present  not  clearly 
protected  In  all  Uember  States  by  existing 
legislation.  administrative  practice  and 
court  Jurisprudence;  and  such  protection. 
where  It  exIsts.  Is  not  the  same  or  has 
different attributes; 
AMENDED  PROPOSAL 
(14)  Unchanged 
(15)  Unchanged 
(16)  Unchanged 
(17)  Unchanged - 7  -
ORIGINAL  PROPOSAL 
(10)  Whereas  the  uncoordinated  development 
In  the  Community  of  the  legal  protection of 
biotechnological  Inventions  In  the 
Member  states  could  result  In  the  creation 
of  new  disincentives  to  trade  to  the 
detriment  of  further  Industrial  development 
In  such  Inventions  and  of  the  completion of 
the  •nternal  market; 
( 11)  Whereas  existing  differences  having 
such  effects  need  to  be  removed  and  new 
ones  having  a  negative  Impact  on  the 
functioning  of  the  common  market  and  the 
development  of  trade  In  biotechnological 
goods  and  services prevented  from  arising; 
(12)  Whereas  International  developments  In 
the  field  of  legal  protection  of  the 
result.s  of  biotechnology  and  genetic 
enqlneer lng  demonstrate  the  advantages  to 
be,',  gained  from  approximation  of  national 
- ...  : .. _  . 
legislation; 
(1~) Whereas  scientific  and  technological 
~evelopments  are  often  a  result  of 
international  collaboration  on  research 
and-;  In  conseQuence.  need  exIsts  to  ensure 
biotechnological  Inventions  may 
be,nef it  from  comparable  protect ion  on  an 
..  ' 
int.ernat lona I  I  eve I; 
AMENDED  PROPOSAL 
(18)  Unchanged 
(19)  Unchanged 
(20)  Unchanged 
(21)  Unchanged - 8  -
ORIGINAL  PROPOSAL 
(14)  Whereas 
Instruments 
although  International 
exist  or  are  under 
consideration  to  harmonize  various  aspects 
of  the  legal  protection of  biotechnological 
inventions.  they  are  not  sufficient  for 
Community  purposes  which  must  take  account 
of  the  needs  of  Community  science  and 
Industry and  a  Community  market; 
(15)  Whereas  the  patent  laws  applicable  at 
present  In  the  Uember  States  contain 
disparities which  hinder  the  development  of 
trade  in  biotechnological  goods  and 
services.  distort  competition  within  the 
common  market  and  therefore directly affect 
the  establishment  and  functioning  of  that 
market;  whereas  It  Is  particularly 
Important  to  remove  these  dlspar It les 
because.  at  the  stage  reached  at  present  In 
establishing the  common  market.  there would 
appear  to  be  an  urgent  need  to  ensure  that 
undertakings 
possibility 
equivalent 
will  be 
of  obtaining 
offered 
effective 
legal  protection  In 
Uember  States  for  the  results  of 
research  activities  In  any  part  of 
Community; 
the 
and 
all 
their 
the 
:-:f. 
AMENDED  PROPOSAL 
(22)  Unchanged 
(23)  Unchanged 
.. 
,"l· 
:  ~\·.)···  . 
•.,··: 
. '· 
:,··. - 9-
ORIGINAL  PROPOSAL  AMENDED  PROPOSAL 
(16)  Whereas  an  approx I  mat Jon  of  the.  (24)  Unchanged 
legislation  of  the  Member  States  Is 
also necessitated by  existing  language 
In  national  laws  originating  In 
certain  International  patent  and  plant 
variety  conventions  which  have  given 
rise to considerable uncertainty as  to 
the  possibility.  of  protecting 
biotechnological  Inventions concerning 
plant  matter  and  microbiological 
Invent Ions,  language  such  as  the 
exclusion  from  patentability of  plant 
and  animal  varieties  and  of 
assent I  a II y  b lo log I  ca I  processes  for 
the production of plants and  animals; 
( 17)  Whereas  It  Is  necessary  to 
encourage  potential  Innovation  In  the 
full  range  of  human  endeavours  by 
recognizing  that  human  Intervention 
which  consists  of  more  than  the 
selection  of  biological  material  and 
allowing  such  material  to  perform 
Inherently  biological  functions  under 
natural  conditions  should  be 
considered  patentable  subject-matter 
and  should not  be  regarded essentially 
biological; 
(25)  Whereas  It  Is  necessary  to 
encourage  potential  Innovation  In  the 
full  range  of  human  endeavours  by 
recognizing  that  human  Intervention  and 
Its  Impact  on  the  result  achieved  must 
be  taken  Into  account  In  determining 
whether  the exclusion  from  patentability 
of  essentially  biological  processes 
applies,  It  being  understood  that  a 
process  whIch,  taken  as  a  who I  e.  does 
not  exist  In  nature  and  Is  more  than  a 
mere  production process  Is  patentable; - 10  -
ORIGINAL  PROPOSAL 
(18)  Whereas  It  Is  seemly  that  the 
legislation  of  the  Member  States 
should  be  harmonized  In  such  a  way  so 
as  not  to  conflict  with  the  existing 
International  conventions  on  which 
many  Member  States'  patent  and  plant 
variety  laws  are  based; 
(19)  Whereas  the  Community's  legal 
framework  on  the  protection  of 
biotechnological  Inventions  can  be 
certain  limited  to  laying  down 
principles  as  they  apply  to  the 
patentab Ill ty  of  II vI ng  matter  as 
such;  to the ability to use a  deposit 
mechanism  In  lieu  of  wr ltten 
descriptions  to  satisfy  the  enabling 
disclosure  requirements  for  patent 
application procedures;  to a  reversal 
of  the  burden  of  proof  where  reI ease 
AMENDED  PROPOSAL 
(26)  Unchanged 
(27)  Whereas  the  Community's  legal 
framework  on  the  protection  of 
biotechnological  Inventions  can  be 
limited  to·  laying  down- certain 
principles  as  they  apply  to  the 
patentability of  biological  materIa I.  as 
such;  to  the  ability  to  use  a  deposit 
mechanism  In  lieu  of  wrItten 
descriptions  to  satisfy  the  enabling 
disclosure  requirements  for  patent 
app II cat Jon  procedures;  to  a  reversal 
of  the  burden  of  proof;  and  to  the right 
of self-repl !cable matter  has occurred  to  a  non-exclusive  compulsory  licence 
and  to  the  right  to  a  non-exclusive  for  plant  varieties; 
dependency  I I  cence  for  pI ant  and 
animal  varieties; - 11  -
ORIGINAL  PROPOSAL 
(20)  Whereas.  In  view of  the  fact  that 
the  function  of  a  patent  Is  to  reward 
the  Inventor  with  an  exclusive  but 
time-bound  right  for  his  creative 
efforts  and  thereby  encourage 
Inventive  activities.  the  rlghtholder 
should  be  entitled to prohibit  the use 
of  patented  self-repl lcable  material 
In  situations analogous  to those where 
It  would  be  permitted  to prohibit  such 
use  of  patented.  non-self-replicable 
products.  I . e.  In  respect  of  the 
production  of  the  patented  product 
Itself; 
(21)  Whereas.  In  the  area  of 
·agricultural  exploitation of  new  plant 
characteristics resulting from  genetic 
engIneerIng.  guaranteed  remunerated 
access  In  the  form  of  II cences  of 
right  must  be  provided  for  as  an 
exception to  the general  principles of 
patent  law. 
HAS  ADOPTED  THIS  DIRECTIVE: 
AMENDED  PROPOSAL 
(28)  Unchanged 
Deleted 
(29)  Whereas  complementary  measures  of 
Community  law  can  be  adopted  later.  If 
necessary.  In  order  to  ensure 
consIstency  between  patent  I  aw  and  the 
plant  varieties protection regime. 
HAS  ADOPTED  THIS  DIRECTIVE: - 12  -
ORIGINAL  PROPOSAL 
CHAPTER  I 
Patentability of Living Matter 
Article 1 
uember  States  shall  ensure  that  their 
nat lonal  patent  laws  comply  with  the 
provisions of  this Directive. 
Article  2 
A subject-matter of an  Invention shall 
not  be  considered unpatentable  for  the 
reason  only  that  It  Is  composed  of 
living matter. 
AUENDED  PROPOSAL 
CHAPTER  I 
Patentability of biological  material 
Article 1 
Uember  States  shall  ensure  that  legal 
biotechnological  protection  for 
Inventions  on  the  basis  of  their 
national  patent  laws  complies  with  the 
provisions of  this Directive. 
Article 2 
1.  A  subject-matter  of  an  Invent I  on 
shall  not  be  considered  unpatentable 
for  the  reason  only  that  It  is 
composed  of,  uses  or  Is  app 1 I  ed  to 
biological  material. 
2.  •slologlcal  material"  within  the 
meanIng  of  thIs  DIrectIve  means  any 
self-replicating  living  matter  and 
any  matter  capable  of  being 
replicated  through  a  biological 
system  or  by  any  Indirect  means. 
3.  Invent Ions 
unpatentable 
exploitation 
contrary  to 
morality, 
sha I I  be  cons I  de red 
where  publication  or 
thereof  would  be 
pub I I  c  poI Icy  or 
provided  that  the 
exploitation  shall  not  be  deemed  to 
be  so  contrary  mere I  y  because  It  Is 
prohibited  by  law  or  regulation  In 
some  or all  of  the Uember  States. - 13  -
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On  this basis.  the  following  Inter alia 
shall  be  unpatentable: 
(a)  the  human  body  or  parts  of  the 
human  body  oer  se; 
(b)  processes for  modifying  the genetic 
IdentIty  of  the  human  body  for  a 
non-therapeutic  purpose  which  Is 
contrary  to  the dignity of  man; 
(c)  processes  for  modifying  the genetic 
Identity  of  animals  which  are 
likely  to  Inflict  suffering  or 
4. 
physical  handicaps  upon  them 
without  any  benefit  to  man  or 
anima I. 
ThiS  Dl rect lve  shall  not  affect 
national  and  eommun I ty  laws  on  the 
monl tor lng  of  the  app II cat Ions  of 
research  and  of  the  use  or 
commercialization of  its results. - 14  -
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Article  3 
1.  Micro-organisms,  biological 
classifications  other  than  plant  or 
animal  varieties  as  well  as  parts  of 
plant  and  animal  varieties  other  than 
propagating material  thereof of  the kind 
protectable  under  plant  variety 
protection  I aw  sha I I  be  cons I  de red 
patentable  subject-matter.  Claims  for 
classifications  higher  than  varieties 
shall  not  be  affected  by  any  rights 
granted  in  respect  of  plant  and  animal 
varieties. 
2.  Notwithstanding  the  provisions  of 
paragraph  1,  plants  and  plant  material 
sha l I  be  cons I  de red  patentab I  e 
subject-matter  unless  such  material  Is 
produced  by  the  non-patentable  use  of  a 
previously 
process. 
Article 4 
known  biotechnological 
Uses  of  plant  or  animal  varieties  and 
processes  for  the  production  thereof  shall 
be  considered patentable subject-matter. 
AMENDED  PROPOSAL 
Article  3 
Biological  material,  Including  plants 
and  animals,  as well  as parts of plants 
and  animals,  except  plant  and  animal 
varieties,  shal I  be  patentable. 
Deleted 
Article 4 
Uses  of  plant  or  animal  varieties or  of 
processes  for  their  product ion,  other 
than  essential Jy  biological  processes, 
shall  be  patentable. ORIGINAL  PROPOSAL 
Article  5 
~icrobiologlcal  processes  shall 
considered patentable subject-matter. 
- 15  -
be 
For 
purposes of  this  Dlrectlv~.  this  term  shall 
be  taken  to  mean  and  to  Include  a  process 
(or  processes)  carried out  with  the  use  of 
or  performed  upon  or  resulting  in  a 
micro-organism. 
Article 6 
A  process  consisting  of  a  succession  of 
steps  shall  be  regarded  a  microbiological 
process.  If  the essence of  the  Invention  Is 
Incorporated  In  one or more  microbiological 
steps of  the  process. 
Article 7 
A  process  in  which  human  Intervention 
consists  In  more  than  selecting  an 
available  biological  material  and  letting 
It  perform  an  inherent  biological  function 
under  natura 1  condItIons  sha II  be 
considered patentable subject-matter. 
~ENDED PROPOSAL 
Article 5 
1.  ~lcroblologlcal  processes  shall  be 
patentable.  For  the  purposes  of 
this  Directive.  "microbiological 
process"  means  a  process  I  nvo I  vi ng 
or  performed  upon  or  resu It l ng  in 
microbiological  material. 
2.  A process consisting of  a  succession 
of  steps  shall  be  treated  as  a 
microbiological  process  if  at  least 
one  essential  step of  the  process  is 
microbiological. 
Deleted 
Article 6 
Essentially  biological  processes  shal I 
not  be  patentable.  In  determining 
whether  this  exclusion  applies.  human 
Intervention  and  Its  impact  on  the 
result  achieved  shal 1  be  taken  into 
account.  A process  which.  taken  as  a 
whole.  does  not  exist  in  nature  and  is 
more  than  a  mere  production  process 
shall  be  patentable. - 16  -
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Article 8 
A subject-matter  of  an  Invention,  including 
a  mixture,  which  formed  an  unseparated part 
of  a  pre-ex i st i ng  mater I  a I ,  sha I I  not  be 
considered unpatentable  for  the  reason only 
that  it  formed  part  of  said  natural 
material. 
Article 9 
A subject-matter  of  an  invention,  Including 
a  mixture,  which  formed  an  unseparated part 
of  a  pre-existing  material,  shall  not  be 
considered  as  an  unpatentable  discovery  or 
as  lacking  novelty  for  the  reason only  that 
It  formed  part  of  said natural  material. 
AMENDED  PROPOSAL 
Article 7 
An  Invention  concerning  a  biological 
material  shall  not  be  considered  a 
discovery or  lacking  In  novelty  for  the 
reason  only  that,  although  not  known, 
It  formed  part of  an  existing material. 
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CHAPTER  I I 
Scope of Protection 
Article  10 
The  use  of  a  product  protected  by  a  patent 
comprising  or  consisting  of  genetic 
information  to develop  another  such  product 
or  the  use  of  a  patented  process  to obtain 
such  a  product  shall  not  be  regarded 
experimental  for  purposes  of  establishing 
patent  infringement.  if  the  developed 
product  obtai ned  from  the  experiments  or 
its  progeny  In  Identical  or  differentiated 
form.  Is  used  for  other  than  private  or 
experimental  purposes. 
Article  11 
If  a  product  enjoying patent  protection and 
put  on  the  market  by  the  patentee  or  with 
his  consent  Is  self-replicable.  the  rights 
conferred  by  the  national  patent  shall  not 
extend  to  acts  of  multiplication  and 
propagation  only  where  such  acts  are 
unavoidable  for  commercial  uses  other  than 
multiplication and  propagation. 
AMENDED  PROPOSAL 
Deleted 
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Article 8 
Uethods  for  treatment  of  the  human  or 
anima I  body  by  surgery  or  therapy  and 
diagnostic  methods  practised  on  the 
human  or  animal  body  shall  not  be 
patentable.'  This  provision  shall  not 
apply  to  products,  in  particular 
·substances or  compositions,  for  use  in 
any  of  these methods. 
Article 9 
A  process  compr IsIng  a  success  I on  of 
steps  sha I I  not  be  exc I uded  from 
patentab I II ty  for  the  reason  on I y  that 
one  or  more  of  the  steps  involve  a 
surgical,  therapeutic  or  diagnostic 
method  practised  on  the  animal  body. 
The  treatment  or  diagnostic  method 
shal I  not,  however,  be  protected 
per  se. - 19  -
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Article  12 
1.  1  f  the  subject-matter  of  a  patent  Is  a 
process  for  the  production  of  living 
matter  or  other  matter  containing 
genetic  Information  permitting  Its 
multiplication  in  identical  or 
differentiated  form,  the  rights 
conferred  by  the  patent  shall  not  only 
extend  to  the  product  initially obtained 
by  the  patented  process  but  also  the 
identical  or  differentiated  products  of 
the  first  or  subsequent  generations 
obtained  therefrom,  said  products  being 
deemed  also  directly  obtained  by  the 
patented  process. 
AMENDED  PROPOSAL 
CHAPTER  II 
Scope of protection 
Article 10 
1.  The  protection conferred  by  a  patent 
on  a  biological  material  possessing, 
as  a  resu It  of  the  Invent ion, 
specific  characteristics  shall 
extend  to  all  biological  materials 
derived  from  that  biological 
material  through  multiplication  or 
propagation  and  possessing  the  same 
characteristics. - 20  -
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2.  Any  extension  of  the  protection 
conferred  by  the  patent  to  a  process  as 
Indicated  under  paragraph  1  to a  product 
obtaI ned  thereby  sha II  not  be  affected 
by  an  exclusion  of  plant  or  animal 
varieties from  patentabi I lty. 
AMENDED  PROPOSAL 
2.  The  protection conferred  by  a  patent 
on  a  process  that  enables  the 
production  of  a  biological  material 
possessing,  as  a  result  of  the 
invention,  specific  characteristics 
shall  extend .to  biological  material 
directly obtained using  that  process 
and  to any  other  biological  materia! 
derived  from  such  biological 
material  through  multiplication  or 
propagation  and  possessing  the  same 
characteristics.  This extension of 
protection  shall  not  be  affected  by 
the  exclusion  from  patentability  of 
plant  and  animal  varieties  provided 
for  In  Article 3 of  this Directive. 
Article  11 
The  protection  referred  to  In 
Art I  c I  e  10  sha I I  not  ex tend  to 
biological  material  derived  from 
biological  material  that  has  been 
marketed  by  the  patent  holder  or  with 
hIs  consent  If  the  mu It I  pI I cat I  on  or 
propagation  result  from  the  application 
for  which  the material  was  marketed. - 21  -
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Article  13 
The  protection  for  a  product  consisting  of 
or  containing  particular  genetic 
information  as  an  essential  characteristic 
of  the  Invention  shal I  extend  to  any 
products  in  which  said  genetic  Information 
has  been  incorporated  and  is  of  essent I  a I 
Importance  for  Its  Industrial  applicability 
or  uti I lty. 
AMENDED  PROPOSAL 
Article  12 
The  protection conferred  by  a  patent on 
a  product  contaInIng  or  consIstIng  of 
genetic  Information  shal I  extend  to all 
material  In  which  the  product  is 
incorporated  and  In  which  the  genetic 
information  is contained and  expressed. 
Article  13 
1.  By  way  of  derogation  from  Chapter  II 
of  this  Directive,  farmers  may  use 
for  purposes  of  multiplication  or 
propagation  on  theIr  own  farms  the 
seeds obtained  from  crops cultivated 
on  their 
protected 
own  farms  using  seeds 
by  patent.  Only 
multiplication or  propagation with  a 
view  to  producing  crops  for  the 
farmers  concerned  can  be  authorized. 
2.  By  way  of  derogation  from  Chapter  II 
of  this  DirectIve,  farmers  rearing 
I ivestock  protected  by  patent  may 
use  it  for  multiplication  purposes 
on  their  own  farms  to  renew  their 
stock. - 22  -
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CHAPTER  Ill 
Dependency  Licence  for  Plant Varieties 
Article  14 
1.  If  the holder of  a  plant  breeders'  right 
or  a  variety  certificate  can  exploit  or 
.exercise  his  exclusive  rights  only  by 
infringement  of  the  rights attached  to a 
pr lor  nat lona I  patent,  a  non-exc Ius i ve 
1 I  cence  of  rIght  sha I I  be  accorded  to 
the  breeders'  right  holder  to  the extent 
necessary  for  the  exploltat ion  of  such 
breeders' 
protected 
right  where  the  variety 
represents  a  significant 
technical  progress,  upon  payment  of 
reasonable  royalties  having  regard  to 
the  nature of  the  patented  Invention and 
consistent  with  giving  the  proprietor of 
such  patent  due  reward  for  the 
Investment  leading  to and  developing  the 
Invention. 
2.  A  II cence  under  paragraph  1  sha II  not 
be  available  prior  to  the  expiration  of 
three years  from  the  date  of  the  grant 
of  the  patent  or  four  years  from  the 
date  on  which  the  application  for  a 
patent  was  filed,  whichever  period  last 
expires. 
AMENDED  PROPOSAL 
CHAPTER  Ill 
Compulsory  licence 
Article 14 
1.  If  the  holder  of  a  patent  on  a 
biotechnological  invention  refuses 
to  allow  another  party  who  Is  the 
holder  of  a  plant  variety  right  to 
use  the  invention  in  return  for  an 
appropriate  royalty,  a  non-exclusive 
compulsory  licence  may  be  sought 
from  the  competent  authority  and  It 
shal I  be  granted  upon  payment  of  an 
appropriate  royalty  If  this  is  In 
the  public  Interest. 
2.  Each  Member  State  shall  designate 
the  authority  competent  to  grant 
I i cences  and  sha I I  inform  the 
Commission  of  each  licence granted. - 23  -
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3.  If  a  licence  according  to  paragraph1 
has  been  granted,  and  If  a  variety 
protected  by  a  plant  breeders'  right  or 
variety  certificate  can  be  exploited  by 
the  patentee only  by  Infringement  of  the 
rights  attached  to  such  variety,  a 
non-exclusive  licence  shall  be  accorded 
to  the  original  patentee  to  the  extent 
necessary  for  the  exploitation  of  the 
breeders•  right  or  variety  certificate, 
upon  payment 
having  regard 
of 
to 
reasonable 
the  nature 
royalties 
of  the 
improvement  and  consIstent  wIth  gIvIng 
the  proprietor  of  the  breeders'  right 
due  reward  for  the  investment  leading  to 
and  developing  the new  variety. 
4.  Where  disagreements arise with  regard  to 
the  significance  of  the  technical 
progress  and  as  to  the  level  of 
royalties,  Member  States  shal I  provide 
for  a  court of  competent  jurisdiction to 
resolve  the dispute. 
AMENDED  PROPOSAL 
3.  If  the  holder  of  a  plant  variety 
right  refuses  to allow another  party 
who  Is  the  hoI der  of  a  patent  to 
engage  In  activities  requiring  his 
consent  on  reasonable  terms,  a  non-
axe I  us I  ve  compu I  sory  I I  cence  may  be 
sought  from  the  competent  authority 
and  it shall  be  granted upon  payment 
of  an  appropriate  royalty  If  this  Is 
In  the  publ lc  Interest. 
4.  An  appea I  sha I I  1 I  e  from  decIsIons 
of  the  competent  authorIty  to  the 
courts. - 24  -
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CHAPTER  IV 
Deposit.  Access  and  Re-Deposit 
Article  15 
1.  If  an  Invention  Involves  the  use  of  a 
micro-organism  or  other  self-replicable 
matter  which  Is  not  aval lable  to  the 
public  and  which  cannot  be  described  in 
a  patent  application  In  such  a  manner  as 
to  enable  the  Invention  to  be  carried 
out  by  a  person  skI lied  In  the  art,  or 
If  It  concerns  such  matter  per  se,  the 
Invention  shall  only  be  regarded  as 
being disclosed  for  purposes of national 
patent  law  If: 
(a)  the  micro-organism  or  other 
self-replicable  matter 
deposited  with  a 
has  been 
recognized 
depositary  Institution  not  later 
than  the  date  of  fl I lng  of  the 
app I I  cat I on ; 
(b)  the application as  filed gives  such 
relevant  Information  as  Is 
available  to  the  applicant  on  the 
characteristics 
micro-organism 
of 
or 
self-replicable matter; 
the 
other 
AMENDED  PROPOSAL 
CHAPTER  IV 
Deposit.  access and  re-deposit 
Article  15 
1.  Where  an  Invention  Involves  the  use 
of or  concerns  a  biological  material 
which  Is  not  available  to the  public 
and  which  cannot  be  descr I  bed  In  a 
patent  application  In  such  a  manner 
as  to  enable  the  Invention  to  be 
carried  out  by  a  person  skilled  In 
the  art,  the  description  sha II  be 
considered  inadequate  for  the 
purposes of  patent  law  unless: 
(a)  the  biological  material  has  been 
deposited,  no  later  than  the 
date  on  which  the  patent 
app I i cation  was  flied,  at  least 
with  an  authorized  Institution 
In  accordance  with  the 
provisions 
Budapest  Treaty 
of 
on 
the 
the 
International  Recognition of  the 
Deposit  of  Ulcroorganlsms  for 
the Purposes of  Patent  Procedure 
of  28  Apr i I  1977; 
(b)  the  app I i cat ion  as  flied 
contains  such  relevant 
Information  as  Is  available  to 
the  depositor  on  the 
characteristics  of  the 
biological  material  deposited; - 25  -
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(c)  the  depositary  Institution  and  the 
file  number  of  the  deposit  are 
~tated  In  the application. 
2.  The  lnformat ion  referred  to  In 
paragraph  1(c)  may  be  submitted: 
(a)  within  a  period  of  sixteen months 
after  the  date  of  fIll ng  of  the 
application  or.  If  priority  Is 
claimed.  after  the priority date; 
(b)  up  to  the  date  of  submission  of  a 
request  for  early  publ !cation  of 
the  app II cat ion; 
(c)  within one  month  after  the national 
patent  office  has  communicated  to 
the  applicant  that  a  right  to 
inspectl·on  of  the  files  exists 
pursuant  to  paragraph  3(a) (II) 
below. 
The  rul lng  period  shal I  be  the  one 
which  Is  the  first  to  expire.  The 
communication of  this  Information shall 
be  cons I  de red  as  constItutIng  the 
unreserved  and  I r revocab I  e  consent  of 
the  applicant  to  the  deposited  matter 
being  available  to  the  public  in 
accordance with  this Article. 
AMENDED  PROPOSAL 
(c)  the  patent  application  states 
the  name  of  the  author I  zed 
depositary  institution  and  the 
accession  number  Identifying  the 
deposited biological  material. 
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3.(a)  Unless  the  application  has  been 
refused  or  withdrawn  or  is  deemed  to 
be  withdrawn,  the  deposited  matter 
shall  be  available upon  request: 
(I)  to  any  person  from  the  date  of 
publication  of  the  patent 
app I I  cat I  on,  and 
(I I)  to any  person  having  a  right  to 
Inspect  the  files  under  the 
provisions  of  national  patent 
law  relating.  to  applications 
under  which  rights  are  invoked 
against  such  a  party,  prior  to 
the date of  publication; 
(b)  Subject  to  the  provisions  of 
paragraph  4,  such  availability shall 
be  effected by  the  Issue of  a  sample 
of  the  deposited  matter  to  the 
person  making  the  request 
(hereinafter  referred  to  as  the 
"requester").  Said  issue  shall  be 
made  only  If  the  requester  has 
undertaken  vis-a-vis  the  appl lcant 
for  or  proprietor  of  the patent: 
AMENDED  PROPOSAL 
2  ..  Access  to  the  deposIted  b lolog lea I 
mater I  a I  sha I I  be  provIded  through 
the supply of  a  sample: 
(a)  up  to  the  first  pub I I  cat ion  of 
the  patent  application,  to  only 
those  persons  who  are  authorized 
under  national  patent  law; 
(b)  between  the  first  pub! !cation  of 
the  application  and  the  granting 
of  the  patent,  to  anyone 
requesting  It  or,  If  the 
depositor  so  requests,  only  to an 
Independent  expert; 
(c)  after  the  patent  has  been 
granted,  to anyone  requesting  it. 
3.  Unless  the  patent  holder  or 
app I I  cant ,  as  app I I  cab I e,  abandons 
his  rights,  the 
supp I I  ed  on I  y 
sample 
If  the 
requesting  it  undertakes, 
duration  of  the  validity 
patent: 
can  be 
person 
for  the 
of  the - 27  -
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(I) 
( I I) 
not  to  make  the  deposIted 
matter  or  any  matter  derived 
therefrom  available  to  any 
third party; 
to  use  the  deposited  matter  or 
any  matter  derIved  therefrom  In 
any  country  only  for 
experimental  purposes 
concerning  the  Invention,  with 
the  proviso  that  this 
restriction  will  cease,  In  the 
country  of  the  patent  right  on 
the  basis  of  which  the  sample 
of  the  deposited  matter  was 
obtained,  with  the  grant  of  a 
patent  or  other  enforceable 
right  In  the  Invention 
Involved.  This  provision 
shal I  not  apply  In  the  country 
of  the  patent  right  on  the 
basis  of  which  the  sample  of 
the  deposited  matter  was 
obtained  in  so  far  as  the 
reQuester  is  using  the  matter 
under  a  compulsory  licence. 
The  term  "compulsory  licence" 
shall  be  construed as  Including 
ex  officio  I i cences  and  the 
right  to 
inventions 
Interest. 
In 
use 
the 
patented 
public 
AMENDED  PROPOSAL 
(a)  not  to  make  It  or  any  matter 
derIved  therefrom  ava II ab I  e  to 
third parties; 
(b)  not  to  use  It  or  any  matter 
derived  therefrom  In  any  country 
except 
purposes. 
for  experimental - 28  -
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4.  Unt I I  the  date  on  whIch  the  techn I  ca I 
preparations  for  publication  of  the 
application  are  deemed  to  have  been 
completed,  the  applicant  may  Inform  the 
nat iona I  patent  off Ice  that.  unt II  the 
publication of  the  mention  of  the  grant 
of  the  patent,  the availability referred 
to  In  paragraph  3  shall  be  effected only 
by  the  Issue  of  a  sample  to  an  expert 
nominated  by  the  requester. 
5.  The  following  may  be  nominated  as  an 
expert: 
(a)  any  natural  person  provided  that 
the  requester  furnishes  evidence, 
when  filing  the  request,  that  the 
nomination  has  the  approval  of  the 
app It cant; 
(b)  any  natural  person  recognized as an 
expert  by  the  nat lona I  patent 
office.  The  nomination  shall  be 
accompanied  by  an  undertaking  from 
the expert  vls-~-vls the applicant; 
paragraphs 3(b)(i)  and  (I I)  shal I 
apply,  the  requester  being  regarded 
as a  third party. 
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6.  For  the  purposes  of  paragraph 3(b),  any 
matter  derived  from  the deposited matter 
shall  be  deemed  to be  any  matter  derived 
therefrom  by  cuI turIng  or  In  any  other 
way  of  replication  which  matter  still 
exhibits  those  characteristics  of  the 
deposited  matter  which  are  essential  to 
or  for  carrying out  the  Invention.  The 
undertaking  referred  to  In 
paragraph  3(b)  shal I  not  impede  a 
deposit of  derived matter,  necessary  for 
the  purposes of  patent  procedure. 
7.  The  request  provided  for  in  paragraph  3 
shall  be  submitted  to  the  national 
patent  offIce  on  a  form  recognIzed  by 
that  office.  The  national  patent 
office  shall  certify on  the  form  that  a 
national  patent  application referring  to 
the  deposit  of  the  micro-organism  or 
other  self-rep I icable  matter  has  been 
filed,  and  that  the  requester  or  the 
expert  nominated  by  him  Is  entitled  to 
the  Issue  of  a  sample  of  the 
micro-organism  or  other  self-replicable 
matter. 
8.  The  national  patent  office  sha II 
transmit  a  copy  of  the  request,  with  the 
certification  provided  for  In 
paragraph  7  to  the  depositary 
Institution  as  well  as  to  the  applicant 
for,  or  the proprietor of,  the  patent. 
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9.  Member  States shal I  designate  recognized 
depositary  Institutions  for  purposes  of 
this Article. 
10.  If  a  micro-organism  or  other 
self-replicable  material  has  been 
deposited  In  accordance  with 
paragraphs  1  and  2  and  has  become 
available  to any  person or  an  expert  In 
accordance  with  paragraphs  3  or  4,  it 
shal I  henceforth  be  regarded  available 
to  the  public  in  accordance  with 
paragraph  1. 
Article  16 
1.  If  a  micro-organism  or  other 
self-rep I !cable  matter  deposIted  in 
accordance  with  Article  15  ceases  to  be 
available  from  the  Institution  with 
which  it was  deposited  because: 
(a)  the  micro-organism  or  other 
self-rep! !cable matter  Is no  longer 
viable,  or 
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4.  At  th~ depositor's  request,  where  an 
application  is  refused  or  withdrawn 
or  a  patent  is  revoked  or  cancelled, 
access  to  the  deposited  material 
sha I I  be  I i  m  I ted  to  an  Independent 
expert  for  twenty  years  from  the 
date on  which  the patent  application 
was  filed.  In  the  above-ment loned 
case,  the  provisions  of  paragraph  3 
shall  apply. 
Article 16 
If  the  biological  material  deposited  in 
accordance with Article  15  ceases  to be 
available  from  the  authorized 
deposItary  I  nst i tut ion,  a  new  deposIt 
of  the  material  shall  be  permitted  in 
accordance  with  the  provisions  of  the 
Budapest  Treaty  on  the  International 
Recogn It I  on  of  the  Oepos It  of 
Microorganisms  for  the  Purposes  of 
Patent  Procedure of  28  April  1977. - 31  -
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2. 
(b)  for  any  other  reason  the depositary 
institution  Is  unable  to  supply 
samples,  and  If  the  micro-organism 
or  other self-replicable matter  has 
not  been  transferred  to  another 
depositary  Institution  recognized 
for  the  purposes  of  Article 15, 
from  which  It  continues  to  be 
In 
ava liable,  an  interruption  In 
availability shall  be  deemed  not  to 
have  occurred  If  a  new  deposIt  of 
the  micro-organism  or  other 
self-replicable  matter  originally 
deposited  Is  made  within  a  per lod 
of  three months  from  the  date  on 
which  the  depositor  was  notified of 
the  Interruption  by  the  depositary 
Institution  and  If  a  copy  of  the 
receIpt  of  the  deposIt  Issued  by 
the  Institution  Is  forwarded  to  the 
national  patent  office  WIth in 
four  months  from  the  date  of  the 
new  deposit  stating  the  number  of 
the  application  or  of  the  national 
patent. 
the  case  provided  for  in 
paragraph  Ha>.  the .new  deposIt  sha I I  be 
made  WIth  the  deposItary  institution 
WIth  which  the  original  deposit  was 
made;  In  the  cases  provided  for  in 
paragraph  1(b).  It  may 
another· 
recognized 
depositary 
for  the 
Article 15(9). 
be  made  with 
Institution 
purposes  of 
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3.  Where  the  Institution  with  which  the 
or I gIna I  deposIt  was  made  ceases  to  be 
recognized  for  the  purposes  of  the 
app II cat I  on  of  Article 15,  whether 
entirely  or  for  the  kind  of 
micro-organism  or  other  self-replicable 
matter  to  which  the  deposited 
micro-organIsm  or  other  se If-rep  I I  cab I e 
matter  belongs,  or  where  that 
Institution discontinues,  temporarily or 
definitively,  the  performance  of  Its 
functions  as  regards  deposited 
micro-organisms or  other self-replicable 
matter,  and  the notification referred  to 
In  paragraph  1  from  the  depositary 
Institution  Is  not  received  within  six 
months  from  the  date of  such  event,  the 
three-month  period  referred  to  In 
paragraph  1  shall  begin  on  the  date  on 
which  this  event  Is  announced  In  the 
official  publication  of  the  national 
patent office. 
4.  Any  new  deposit  shall  be  accompanied  by 
a  statement  signed  by  the  depositor 
5. 
alleging  that  the  newly  deposited 
micro-organism  or  other  self-replicable 
matter  Is  the  same  as  that  originally 
deposl ted. 
If  the  new  depos I t  provided  for  in  the 
present  Article  has  been  made  under  the 
Budapest  Treaty  on  the  International 
Recognition  of  the  Deposit  of 
Micro-organisms  for  the  Purposes  of 
Patent  Procedure  of  28  Apr II  1977,  the 
provisions  of  that  Treaty  shal I  prevail 
in  case of conflict. 
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6.  If  a  deposit  is  not  accepted  or  if  the 
7. 
deposited 
available 
material 
from 
Is 
the 
no  longer 
depositary 
institution  and  a  re-deposit  according 
to  paragraphs  (1)  through  (5)  does  not 
or  could  not  remedy  the  unavailability, 
such  unavailability shall  not  affect  the 
patentabi llty  of  the  Invention  If  the 
appl !cant/patentee  provides  the 
requesting  party  entitled  to  receive  a 
sample  with  such  same  certifying  its 
identity  with  the  material  used  in  the 
Invention  or  obtained  as  the  invention 
or  with  the  originally  deposl ted 
material,  as  the  case  may  be. 
If  a  patent  is  deemed  lnval id  because 
the  patentee can  no  longer  provide  for  a 
sample  of  the  deposited  material  in 
accordance  WIth  this  article,  such 
Invalidity  shall  In  no  case  have 
retroactive effects. 
AMENDED  PROPOSAL 
Deleted 
Deleted - 34  -
ORIGINAL  PROPOSAL 
CHAPTER  V 
Reversal  of  the Burden of Proof 
Article 17 
1.  If  the  subject~atter  of  a  patent  Is  a 
process  for  obtaining  a  new  or  known 
product,  the  same  product  when  produced 
by  any  other  party shall,  in  the  absence 
of  proof  to  the  contrary,  be  deemed  to 
have  been  obtained  by  the  patented 
process,  If  a  necessary  means  to  carry 
out  the  process  had  been  deposIted  In 
accordance  with  Article 14  and  had  been 
released  to a  third party. 
2.  In  the  adduction  of  proof  to  the 
contrary,  the  legitimate  interests  of 
the  defendant  in  protecting  his 
manufacturing  and  business secrets shall 
be  taken  Into account. 
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1.  If  the subject-matter  of  a  patent  is 
a  process  for  obtaining 
product,  any  identical 
a  new 
product 
produced  by  any  person  other  than 
the  patent  holder  shall,  in  the 
absence of  proof  to  the  contrary,  be 
deemed  to  have  been  obtained  by 
means  of  the  patented  process. 
2.  In  the  adduction  of  proof  to  the 
contrary,  the  legitimate  interests 
of  the  defendant  in  protectIng  hIs 
manufacturing  and  business  secrets 
shall  be  taken  into account. - 35  -
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CHAPTER  VI 
Ul see I I  aneous 
Article 18 
Any  exc Ius I  on  from  patentab Ill ty  or  from 
the  field  of  Industrial  applicability  of 
surgical  or  diagnostic methods  practised on 
an  animal  body  shall  apply  to  such  methods 
only  If  practised  for  a  therapeutic 
purpose. 
Article  19 
For  the  purposes of  this Directive: 
(a)  the  word  "micro-organism",  where  used, 
sha 1 1  be  1  nterpreted  In  Its  broadest 
sense  as  Including  all  microbiological 
entitles  capable  of  replication,  e.g. 
as  comprising,  Inter  alia,  bacteria, 
fungi.  viruses.  mycoplasmae, 
ricKettsiae,  algae,  protozoa.  and 
ce lis;  and 
(b)  the  words  "self-replicable  matter". 
where  used,  shall  be  Interpreted  to 
comprise  also  matter  possessing  the 
genetic  material  necessary  to  direct 
its own  replication via  a  host  organism 
or  In  any  other  Indirect  way,  e.g.  as 
comprIsing,  inter alia,  seeds, 
plasmlds,  DNA  sequences,  protoplasts, 
repllcons  and  tissue cultures. 
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Article  20 
1.  Member  States shall  bring  into force  the 
laws  necessary  to  comply  with  this 
Directive  not  later  than 
31  December  1990. 
2.  Member  States  shall  communicate  to  the 
Commission  the  texts  of  the  main 
·provisions  of  national  law  which  they 
adopt  In  this  field  covered  by  this 
Directive. 
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Article 18 
1.  The  Member  States  shal I  adopt  the 
laws.  regulations and  administrative 
provisions  necessary  for  their 
compliance  with  this  Directive  not 
later  than 
When  they  adopt  such  measures  the 
Member  States  shall  Include 
references  to  this  Directive  or 
shall  malce  such  references when  they 
effect  official  publication.  The 
manner  in  which  such  references  are 
to  be  made  shall  be  laid  down  by  the 
Member  States. 
2.  The  Uember  States  shall  communicate 
to  the  Commission  the  texts  of  the 
provisions  of  national  law  which 
they  adopt  in  the  field  covered  by 
this Directive. ORIGINAL  PROPOSAL 
Article  21 
This  Directive 
Member  States. 
Done  at Brussels, 
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Article 19 
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